ORCHPHARMA1,010.00

Orchid Pharma Limited

· Pharma & Health
₹ CrorePeersFDCGUJTHEMIOLCPMOREPENLABRPGLIFEGUFICBIOINNOVACAPUNICHEMLABMcap ₹5,123 Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Adjustments to Reconcile Profit — Non-cash Items
+ Depreciation & Amortisation33.234.535.5
+ Finance Costs16.414.513.3
+ Interest Income0.00.08.4
+ Unrealised FX (Gain) / Loss7.6-5.8-7.7
+ Other Non-cash Items-41.20.0-7.2
+ Other Reconciling Items0.70.0-16.8
Changes in Working Capital
+ Inventories-35.5-62.170.0
+ Trade Receivables — Current19.6-49.1-14.1
+ Trade Receivables — Non-current0.06.80.0
+ Other Financial Assets — Non-current0.01.70.7
+ Other Current Assets0.04.5-22.8
+ Other Non-current Assets0.00.30.0
+ Trade Payables — Current54.90.06.1
+ Trade Payables — Non-current0.0-6.80.0
+ Other Current Liabilities-7.30.00.0
+ Provisions — Current-0.30.00.0
+ Provisions — Non-current0.03.212.3
Cash from Operating Activities
Profit Before Tax (per I/S)91.995.621.010.0
+ Total Adjustments (incl. Working Capital)51.0-58.177.5
Cash from Operations (pre-tax)143.037.498.5
+ Interest Received — Operating-16.30.00.0
+ Interest Paid — Operating0.017.30.0
+ Income Taxes Paid0.60.9-2.7
Cash from Operating Activities126.019.2101.2
Cash from Investing Activities
+ Acq of Fixed Assets (Capex)-64.8150.1383.6
+ Disp of Fixed Assets0.00.09.0
+ Acq of Other Long-term Assets4.30.00.0
+ Purchase of Investments (Equity / Debt)0.00.03.6
+ Receipts on Futures / Forwards / Options / Swaps0.0104.40.0
+ Interest Received — Investing12.018.710.6
+ Other Inflows / (Outflows) — Investing-384.60.082.3
Cash from Investing Activities-312.0-26.9-285.3
Cash from Financing Activities
+ Proceeds from Issue of Shares391.90.00.0
+ Proceeds from Borrowings0.028.6184.7
+ Repayment of Borrowings208.50.212.9
+ Interest Paid16.43.11.9
Cash from Financing Activities167.025.2170.0
Net Changes in Cash (pre-FX)-19.017.5-14.1
Net Changes in Cash-19.017.5-14.1
Closing Cash3.6
Reference Items
EBITDA110.7117.241.141.0
EBITDA Margin %13.5112.715.074.34
Free Cash Flow (CFO − Capex)190.8-130.9-282.4-282.4
Free Cash Flow to Equity-94.2-101.0
Free Cash Flow per Basic Share37.62-25.81-55.68-55.68
Cash Flow to Net Income1.370.194.93
Cash Paid for Taxes0.60.9-2.7
Cash Paid for Interest16.43.11.9
As filed, sign as filed: a payment tagged as a positive magnitude in the filing stays positive here, so read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown — depth follows the filer, so a thin statement means a thin filing. Total Adjustments is the filer's own grand total of the reconciliation and spans BOTH the non-cash items and the working-capital block; Profit Before Tax plus it equals Cash from Operations (pre-tax). It can be reported when its components are not, so it is never a sum of the rows above it. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.